Motegrity (Prucalopride): Side Effects, Dosage, Uses, and More

What Is Motegrity?

Motegrity is the U.S. brand name for prucalopride, a prescription gastrointestinal prokinetic medication. It belongs to a drug class called selective serotonin type 4, or 5-HT4, receptor agonists.

Although the word “serotonin” is often associated with mood, much of the body’s serotonin activity occurs in the digestive system. By selectively activating 5-HT4 receptors, prucalopride promotes the intestinal signals and muscle contractions that propel stool through the colon.

In less scientific language, Motegrity encourages the colon to stop staring at its to-do list and start moving things along.

What is Motegrity approved to treat?

The U.S. Food and Drug Administration has approved Motegrity for the treatment of chronic idiopathic constipation, or CIC, in adults.

“Chronic” means the problem has persisted over time. “Idiopathic” means no specific disease, structural abnormality, or medication has been identified as the primary cause. Symptoms may include:

• Fewer than three bowel movements per week
• Hard, dry, or lumpy stools
• Frequent straining
• Painful or difficult bowel movements
• A feeling that the bowel has not emptied completely

Before diagnosing CIC, a clinician may consider medication-related constipation, thyroid disease, diabetes, pelvic floor dysfunction, irritable bowel syndrome, intestinal obstruction, and other possible explanations.

How Does Motegrity Work?

Prucalopride stimulates colonic peristalsis, including powerful movements known as high-amplitude propagating contractions. These coordinated contractions help move intestinal contents toward the rectum.

Motegrity therefore works differently from many familiar laxatives. Fiber supplements increase stool bulk, osmotic laxatives draw water into the bowel, and stimulant laxatives directly trigger intestinal activity. Prucalopride is classified as a prokinetic agent because it promotes organized gastrointestinal movement.

Clinical studies found that improvement in complete spontaneous bowel movements could appear during the first week. That does not mean everyone will have the same response, however. Some patients notice changes quickly, while others require more time before they and their prescriber can judge whether the medication is helping.

How effective is prucalopride?

Motegrity was evaluated in six randomized, placebo-controlled adult trials lasting 12 to 24 weeks. In five of the six trials, a significantly greater percentage of patients taking prucalopride achieved an average of at least three complete spontaneous bowel movements per week compared with placebo. One 24-week trial did not show a statistically significant difference for the primary endpoint.

The results are encouraging but not magical. Motegrity improves the odds of a meaningful response; it does not guarantee that every patient will suddenly own the world’s most punctual colon.

Joint guidance from the American Gastroenterological Association and American College of Gastroenterology strongly recommends prucalopride as an option for adults with CIC who have not responded adequately to over-the-counter treatments.

Motegrity Dosage

Standard adult dosage

The recommended Motegrity dosage for most adults with chronic idiopathic constipation is:

2 milligrams taken by mouth once daily.

Motegrity is available as 1-mg and 2-mg film-coated tablets. It may be taken with or without food. Taking it at approximately the same time each day can make the routine easier to remember.

Dosage for severe kidney impairment

For patients with severe renal impairment, defined in the prescribing information as a creatinine clearance below 30 mL/min, the recommended dosage is:

1 milligram taken once daily.

No dosage adjustment is generally required for mild or moderate kidney impairment when creatinine clearance is at least 30 mL/min. Motegrity should be avoided in people with end-stage kidney disease requiring dialysis.

Because prucalopride is eliminated mainly through the kidneys, renal function is particularly important in older adults. Age alone does not automatically require a lower dose, but reduced kidney function might.

What if you miss a dose?

Take the missed dose when you remember it unless it is nearly time for the next scheduled dose. In that case, skip the missed tablet and return to the regular schedule. Do not double the dose. Two tablets do not persuade the colon twice as politely.

Can Motegrity be cut, crushed, or taken at night?

Follow the instructions provided by your pharmacist regarding tablet handling. The official dosing instructions do not require a particular time of day. Some patients prefer morning dosing so they can observe early digestive effects while awake; others choose a different time for convenience. Consistency and prescriber guidance matter more than chasing a theoretically perfect hour.

Common Motegrity Side Effects

The most common side effects reported in adult clinical trials included:

• Headache
• Abdominal pain or discomfort
• Nausea
• Diarrhea
• Abdominal bloating or distension
• Dizziness
• Vomiting
• Gas
• Fatigue

In controlled trials, headache occurred in 19% of patients taking Motegrity and 9% taking placebo. Abdominal pain was reported by 16% versus 11%, nausea by 14% versus 7%, and diarrhea by 13% versus 5%.

Headache

Headache often begins early. Among Motegrity users who reported a headache in clinical trials, about two-thirds experienced it during the first two days. For many, it resolved within a few days.

Contact your clinician if a headache is severe, persistent, unusual, or accompanied by weakness, confusion, speech difficulty, vision changes, chest discomfort, or other concerning symptoms.

Diarrhea

Most reported diarrhea began during the first week, and it commonly improved after several days. Severe or prolonged diarrhea can cause dehydration and electrolyte disturbances, so call a healthcare professional if you cannot maintain hydration, feel faint, have very little urine, or experience ongoing vomiting.

Nausea and abdominal discomfort

Nausea, cramping, gurgling, bloating, and abdominal discomfort may occur as intestinal motility changes. Taking the tablet with food may be more comfortable for some people, although food is not required and does not meaningfully reduce drug absorption.

Severe, constant, or worsening abdominal pain should not be dismissed as the bowel “adjusting.” It requires medical assessment, especially when combined with vomiting, fever, swelling, blood in the stool, or an inability to pass gas.

Serious Side Effects and Warnings

Changes in mood, depression, and suicidal thoughts

The Motegrity prescribing information warns about suicidal ideation, suicide attempts, self-injurious thoughts, and new or worsening depression reported during clinical trials and after approval. Some postmarketing reports occurred within the first few weeks of treatment.

A direct cause-and-effect relationship has not been established, but the warning must be taken seriously. Patients, caregivers, and family members should watch for:

• New or worsening depression
• Unusual anxiety, agitation, or behavioral changes
• Thoughts about self-harm or suicide
• Sudden emotional or personality changes
• Nightmares, hallucinations, or severe sleep disturbance

Stop taking Motegrity and contact the prescribing healthcare professional immediately if these symptoms occur. Anyone in immediate danger should call emergency services or the 988 Suicide & Crisis Lifeline in the United States.

Severe allergic reaction

Prucalopride can rarely cause a serious hypersensitivity reaction. Seek emergency care for trouble breathing, wheezing, hives, widespread rash, intense itching, or swelling of the face, lips, tongue, or throat.

Cardiovascular considerations

Earlier, less-selective drugs in the broader 5-HT4 agonist family raised concerns about cardiovascular safety. Prucalopride is more selective. Clinical and observational evaluations in the prescribing information did not demonstrate an increased risk of major adverse cardiovascular events relative to the specified comparisons, and even supratherapeutic testing did not show clinically meaningful QT prolongation.

That does not make chest pain, fainting, severe palpitations, or stroke-like symptoms safe to ignore. Those symptoms always require prompt medical attention.

Who Should Not Take Motegrity?

Motegrity is contraindicated in people with:

• A previous hypersensitivity reaction to prucalopride
• Intestinal perforation
• A structural or functional bowel obstruction
• Obstructive ileus
• Severe inflammatory intestinal conditions, including Crohn’s disease or ulcerative colitis
• Toxic megacolon or toxic megarectum

Tell the prescriber about kidney disease, dialysis, depression, suicidal thoughts or behavior, significant mood disorders, unexplained abdominal symptoms, and all prescription or nonprescription products being used.

Pregnancy and breastfeeding

Human pregnancy data are currently too limited to determine whether prucalopride increases the risk of miscarriage, birth defects, or other adverse outcomes. A pregnancy exposure registry is available for people exposed to Motegrity during pregnancy.

Prucalopride passes into human breast milk. Information about its effects on breastfed infants and milk production is limited. The benefits of treatment and breastfeeding should be weighed against potential risks with an obstetrician, gastroenterologist, pediatrician, or pharmacist.

Use in children

Motegrity is approved in the United States for adults. Its safety and effectiveness have not been established in pediatric patients. A pediatric study did not demonstrate the expected improvement in spontaneous bowel movements and was stopped early for futility.

Motegrity Drug Interactions

Prucalopride has a relatively low potential for major metabolic drug interactions. Studies did not find clinically significant pharmacokinetic changes when it was taken with warfarin, digoxin, paroxetine, certain oral contraceptives, cimetidine, or probenecid.

Ketoconazole increased exposure to prucalopride, while prucalopride increased exposure to erythromycin in an interaction study, but these changes were considered unlikely to be clinically significant in the prescribing information.

Even so, provide the prescriber and pharmacist with a complete list of medications, vitamins, herbal products, and supplements. Also discuss other laxatives. Combining constipation treatments without professional guidance could produce urgent diarrhea, cramping, dehydration, or a bathroom schedule ambitious enough to cancel dinner plans.

Motegrity Compared With Other Constipation Treatments

Doctors commonly begin CIC treatment with lifestyle measures and lower-cost over-the-counter options. These may include gradual fiber supplementation, adequate fluid intake, physical activity, bowel training, polyethylene glycol, magnesium oxide, senna, or short-term rescue use of stimulant laxatives.

Prescription choices include lubiprostone, linaclotide, plecanatide, and prucalopride. Linaclotide and plecanatide increase intestinal fluid secretion, while Motegrity primarily stimulates colonic motility. The best option depends on symptoms, kidney function, previous treatment responses, tolerability, insurance coverage, and whether abdominal pain or diarrhea is already a major concern.

Motegrity should not be confused with medications specifically approved for opioid-induced constipation. It is approved for chronic idiopathic constipation, not constipation with a clearly identified medication-related cause.

Practical Tips for Taking Motegrity

• Take it once daily at approximately the same time.
• Use it with or without food according to personal comfort.
• Do not take more than prescribed to accelerate results.
• Keep a brief diary of bowel movements, stool consistency, pain, urgency, and side effects.
• Drink enough fluid, particularly if diarrhea develops, unless fluid intake is medically restricted.
• Store the tablets in their original container at room temperature and protect them from moisture.
• Do not store the bottle in a steamy bathroom.
• Report mood changes promptly rather than waiting for the next routine appointment.

Continue reasonable lifestyle measures unless a clinician advises otherwise. Adults generally need an appropriate amount of dietary fiber, but adding large quantities too quickly may turn manageable bloating into a one-person brass band. Increase fiber gradually and drink enough liquid to help it work.

When to Contact a Doctor

Contact the prescriber if constipation is not improving, side effects remain troublesome, or diarrhea becomes persistent. Seek prompt or emergency medical attention for:

• Suicidal thoughts or sudden, concerning mood changes
• Trouble breathing or facial, tongue, or throat swelling
• Severe or constant abdominal pain
• Repeated vomiting
• Inability to pass stool or gas with abdominal swelling
• Blood in the stool or rectal bleeding
• Fever or unexplained weight loss
• Signs of severe dehydration

What Taking Motegrity May Feel Like: Experience-Based Scenarios

The following approximately 500-word section describes realistic, composite treatment experiences based on known clinical patterns. It is not a collection of verified individual testimonials and should not be interpreted as a prediction of anyone’s response.

The first few days

A person who starts Motegrity on a quiet Saturday may be glad they did. During the first day or two, they might notice more intestinal noise, mild cramping, a headache, or a quicker-than-usual trip to the bathroom. The colon, after months of moving at the speed of a committee meeting, may suddenly discover deadlines.

Another patient may feel almost nothing at first. That does not necessarily mean the medication has failed. Although some people experience a spontaneous bowel movement quickly, a complete bowel movement may take several days, and overall effectiveness is generally judged over a longer period.

Early diarrhea can be frustrating. Someone expecting a gentle improvement may instead receive a rather enthusiastic response from the digestive system. Keeping water nearby, avoiding unnecessary extra laxatives, and discussing severe symptoms with a clinician can make this adjustment period safer.

The first few weeks

As treatment continues, a successful response may look less dramatic than patients expect. Instead of one spectacular digestive event, improvement might mean bowel movements becoming more frequent, less straining, softer stool, and fewer days dominated by abdominal pressure. The real victory may be leaving the house without mentally mapping every pharmacy and restroom in a five-mile radius.

A bowel diary can reveal progress that memory misses. One patient might believe “nothing has changed,” then notice that bowel movements increased from once every five days to three times per week. Another may discover that frequency improved but pain or urgency became unacceptable. Both observations are useful when discussing whether to continue, adjust, or replace treatment.

Headaches and nausea often settle after the early days, but not always. A patient whose side effects remain disruptive should not assume discomfort is the price of admission. The prescriber may evaluate hydration, kidney function, other medications, dosing, and alternative therapies.

The emotional safety check

The mood warning can feel surprising for a constipation medication, which is exactly why it should be discussed before treatment. A person with a history of depression might ask a partner or family member to watch for unusual behavior during the first few weeks. This is not an invitation to monitor every bad mood like a suspicious detective. It is a practical safety plan for identifying meaningful changes early.

If depression worsens, behavior becomes unusual, or thoughts of self-harm appear, the correct response is not to “give the medicine another week.” Motegrity should be stopped and the healthcare provider contacted immediately, with emergency support used when necessary.

Finding the right long-term plan

Some patients find that Motegrity restores a degree of regularity they had not enjoyed for years. Others experience partial improvement, intolerable diarrhea, headaches, or no worthwhile benefit. A nonresponse is not a personal failure, and it does not mean the symptoms are imaginary. Chronic constipation has several possible mechanisms, including slow transit and pelvic floor dysfunction, and one medication cannot correct every cause.

The most useful experience is therefore an observed and documented one: take the medication correctly, track meaningful outcomes, report side effects honestly, and review the results with the prescriber. Digestive treatment is rarely glamorous, but a plan that makes daily life more predictable deserves a small, dignified celebration.

Frequently Asked Questions

Is Motegrity a laxative?

It is often grouped with prescription constipation medications, but it is more specifically a prokinetic 5-HT4 receptor agonist. It promotes coordinated movement of stool through the colon rather than simply adding bulk or drawing water into the intestine.

How quickly does Motegrity work?

Some patients experience a spontaneous bowel movement during the first day, while a complete spontaneous bowel movement may take several days. Clinical improvement in bowel-movement frequency was seen as early as the first week, but individual responses vary.

Does Motegrity cause weight loss?

Weight loss is not an approved use or a typical expected effect. Unexplained weight loss alongside constipation is a warning sign that should be medically evaluated.

Can you take MiraLAX with Motegrity?

Some treatment plans may combine a prescription agent with an over-the-counter product, but the combination should be approved by the prescriber. Using both may increase diarrhea, cramping, dehydration, or urgency.

Can Motegrity be stopped suddenly?

The prescribing information does not require gradual tapering. However, discuss stopping with the prescriber, particularly when treatment is being discontinued because of side effects or lack of benefit. Stop immediately and contact a healthcare professional for new depression, suicidal thoughts, or unusual behavioral changes.

Conclusion

Motegrity is a once-daily prescription medication for adults with chronic idiopathic constipation. By activating selective 5-HT4 receptors, prucalopride stimulates colonic movement and can improve complete spontaneous bowel movements, particularly when over-the-counter treatments have not provided enough relief.

The usual adult dose is 2 mg daily, reduced to 1 mg daily in severe renal impairment. Headache, abdominal pain, nausea, and diarrhea are the most common side effects and often begin early. The most important precaution is the possibility of new or worsening depression, suicidal thoughts, or unusual behavioral changes, which require immediate discontinuation and medical contact.

Motegrity can be an effective part of a thoughtful constipation treatment plan, but it works best when the diagnosis is correct, kidney function is considered, symptoms are tracked, and the colon is not expected to transform overnight into a Swiss railway system.